Point of care assessment of melanoma tumor signaling and metastatic burden from μNMR analysis of tumor fine needle aspirates and peripheral blood

Jemal, 2010, Cancer statistics, 2010, CA Cancer J Clin, 60, 277, 10.3322/caac.20073 Carlino, 2015, Targeting oncogenic BRAF and aberrant MAPK activation in the treatment of cutaneous melanoma, Crit Rev Oncol Hematol, 10.1016/j.critrevonc.2015.08.021 Korn, 2008, Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials, J Clin Oncol, 26, 527, 10.1200/JCO.2007.12.7837 Puzanov, 2010, Targeted molecular therapy in melanoma, Semin Cutan Med Surg, 29, 196, 10.1016/j.sder.2010.06.005 Sullivan, 2013, Resistance to BRAF-targeted therapy in melanoma, Eur J Cancer, 49, 1297, 10.1016/j.ejca.2012.11.019 Sullivan, 2015, New strategies in melanoma: entering the era of combinatorial therapy, Clin Cancer Res, 21, 2424, 10.1158/1078-0432.CCR-14-1650 Cancer Genome Atlas N, 2015, Genomic classification of cutaneous melanoma, Cell, 161, 1681, 10.1016/j.cell.2015.05.044 Brose, 2002, BRAF and RAS mutations in human lung cancer and melanoma, Cancer Res, 62, 6997 Flaherty, 2010, Inhibition of mutated, activated BRAF in metastatic melanoma, N Engl J Med, 363, 809, 10.1056/NEJMoa1002011 Villanueva, 2010, Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K, Cancer Cell, 18, 683, 10.1016/j.ccr.2010.11.023 Nazarian, 2010, Melanomas acquire resistance to B-RAF (V600E) inhibition by RTK or N-RAS upregulation, Nature, 468, 973, 10.1038/nature09626 Perna, 2015, BRAF inhibitor resistance mediated by the AKT pathway in an oncogenic BRAF mouse melanoma model, Proc Natl Acad Sci U S A, 112, E536, 10.1073/pnas.1418163112 Larkin, 2014, Combined vemurafenib and cobimetinib in BRAF-mutated melanoma, N Engl J Med, 371, 1867, 10.1056/NEJMoa1408868 Lee, 2008, Chip-NMR biosensor for detection and molecular analysis of cells, Nat Med, 14, 869, 10.1038/nm.1711 Issadore, 2012, Ultrasensitive clinical enumeration of rare cells ex vivo using a micro-hall detector, Sci Transl Med, 4, 141ra92, 10.1126/scitranslmed.3003747 Issadore, 2014, Magnetic sensing technology for molecular analyses, Lab Chip, 14, 2385, 10.1039/c4lc00314d Lee, 2015, Recent developments in magnetic diagnostic systems, Chem Rev, 10.1021/cr500698d Haun, 2011, Micro-NMR for rapid molecular analysis of human tumor samples, Sci Transl Med, 3, 71ra16, 10.1126/scitranslmed.3002048 Peterson, 2013, Ascites analysis by a microfluidic chip allows tumor-cell profiling, Proc Natl Acad Sci U S A, 110, E4978, 10.1073/pnas.1315370110 Ghazani, 2013, Comparison of select cancer biomarkers in human circulating and bulk tumor cells using magnetic nanoparticles and a miniaturized micro-NMR system, Nanomedicine, 9, 1009, 10.1016/j.nano.2013.03.011 Samatar, 2014, Targeting RAS–ERK signalling in cancer: promises and challenges, Nat Rev Drug Discov, 13, 928, 10.1038/nrd4281 Ghazani, 2012, Sensitive and direct detection of circulating tumor cells by multimarker micro-nuclear magnetic resonance, Neoplasia, 14, 388, 10.1596/neo.12696 Haun, 2011, Molecular detection of biomarkers and cells using magnetic nanoparticles and diagnostic magnetic resonance, Methods Mol Biol, 726, 33, 10.1007/978-1-61779-052-2_3 Haq, 2013, Oncogenic BRAF regulates oxidative metabolism via PGC1alpha and MITF, Cancer Cell, 23, 302, 10.1016/j.ccr.2013.02.003 Schingelin, 2015, The ImageJ ecosystem: an open platform for biomedical image analysis, Mol Reprod Dev, 82, 518, 10.1002/mrd.22489 Eisenhauer, 2009, New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1), Eur J Cancer, 45, 228, 10.1016/j.ejca.2008.10.026 Davies, 2002, Mutations of the BRAF gene in human cancer, Nature, 417, 949, 10.1038/nature00766 Flaherty, 2012, Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations, N Engl J Med, 367, 1694, 10.1056/NEJMoa1210093 Hatzivassiliou, 2012, ERK inhibition overcomes acquired resistance to MEK inhibitors, Mol Cancer Ther, 11, 1143, 10.1158/1535-7163.MCT-11-1010 Improta, 2015, New developments in the management of advanced melanoma — role of pembrolizumab, Onco Targets Ther, 8, 2535, 10.2147/OTT.S72823 Lucci, 2012, Circulating tumour cells in non-metastatic breast cancer: a prospective study, Lancet Oncol, 13, 688, 10.1016/S1470-2045(12)70209-7 Rack, 2014, Circulating tumor cells predict survival in early average-to-high risk breast cancer patients, J Natl Cancer Inst, 106, 10.1093/jnci/dju066 Krebs, 2011, Evaluation and prognostic significance of circulating tumor cells in patients with non-small-cell lung cancer, J Clin Oncol, 29, 1556, 10.1200/JCO.2010.28.7045 Luo, 2014, Isolation and molecular characterization of circulating melanoma cells, Cell Rep, 7, 645, 10.1016/j.celrep.2014.03.039 Neal, 2015, Developing biomarker-specific end points in lung cancer clinical trials, Nat Rev Clin Oncol, 12, 135, 10.1038/nrclinonc.2014.222